Key gene targets for potential treatment of mental illness, "POU3F2" and "DGCR5"

Schizophrenia, bipolar disorder, is a common multi-gene genetic mental illness.
the genetic mechanism swells because it is influenced by the co-regulation of multiple genes.
to explore the mechanism of treatment of mental illness and find a cure is the goal actively explored by researchers around the world.
, following the publication of genetic "genetic-level" evidence of the pathogenesis of mental illness in the international journal Science on December 14, researchers at Central South University published two important genetic targets for the treatment of mental illness, POU3F2 and DGCR5, in the international journal Science, in two papers on December 19.
series of studies that help reveal the multi-genetic mechanisms of mental illness, which are expected to be used in future drug development for schizophrenia.
article from Chen Chao, Central South University.
the first paper, Transcription Factor POU3F2, regulates the gene co-expression network in brain tissue of people with mental illness, focusing on schizophrenia and bipolar disorder.
study found a co-expression network of genes associated with the disease and identified an important transcription factor gene, POU3F2.
the gene plays a central role in the networks associated with mental illness and can affect the expression changes of multiple downstream genes, and can be an important target for future disease mechanisms and drug development.
the second paper focused on the relationship between long-chain non-coding RNA (ribonucleic acid) and schizophrenia in the region satiating of copies associated with schizophrenia.
studies have found that long-chain non-coding RNA "DGCR5" in the human chromosome 22q11.2 region is closely related to normal neurodevelopment of the human brain, and its expression abnormality can cause a series of expression changes in the genes associated with schizophrenia, which eventually lead to disease.
this achievement, it opened up the functional cognition of the non-coding region of the genome.
as an important regulatory factor associated with the occurrence of schizophrenia, DGCR5 is also expected to be used in future treatment of mental illness.
Source: Science Daily.